<table id="table4" width="75%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4	Potentially Significant Drug Interactions: Alteration in Dosage or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction<footnote id="t4f1">This table is not all-inclusive.</footnote>
</caption>
<col align="left" valign="top" width="25%"></col>
<col align="left" valign="top" width="25%"></col>
<col align="left" valign="top" width="50%"></col>
<thead>
<tr>
<th align="center" stylecode="Lrule Rrule">Concomitant Drug Class: Drug Name</th>
<th align="center" stylecode="Rrule" valign="middle">Effect on Concentration<footnote id="t4f2">↓ = decrease.</footnote>
</th>
<th align="center" stylecode="Rrule" valign="middle">Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antiarrhythmics:</content>
<br/>amiodarone</td>
<td stylecode="Rrule">Effect on amiodarone and sofosbuvir  concentrations unknown</td>
<td stylecode="Rrule">Coadministration of amiodarone with SOVALDI in combination with another DAA may result in serious symptomatic bradycardia. The mechanism of this effect is unknown. Coadministration of amiodarone with SOVALDI in combination with another DAA is not recommended; if coadministration is required, cardiac monitoring is recommended <content stylecode="italics">[see <linkhtml href="#S5.1">Warnings and Precautions (5.1)</linkhtml>, <linkhtml href="#S6.2">Adverse Reactions (6.2)</linkhtml>].</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticonvulsants:</content>
<br/>carbamazepine<br/>phenytoin<br/>phenobarbital<br/>oxcarbazepine</td>
<td stylecode="Rrule">↓ sofosbuvir<br/>↓ GS-331007</td>
<td stylecode="Rrule">Coadministration of SOVALDI with carbamazepine, phenytoin, phenobarbital or oxcarbazepine is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of SOVALDI. Coadministration is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antimycobacterials:</content>
<br/>rifabutin<br/>rifampin<br/>rifapentine</td>
<td stylecode="Rrule">↓ sofosbuvir<br/>↓ GS-331007</td>
<td stylecode="Rrule">Coadministration of SOVALDI with rifabutin or rifapentine is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of SOVALDI. Coadministration is not recommended.<br/>Coadministration of SOVALDI with rifampin, an intestinal P-gp inducer, is not recommended <content stylecode="italics"> [see <linkhtml href="#S5.2">Warnings and Precautions (5.2)</linkhtml>].</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Herbal Supplements:</content>
<br/>St. John's wort <content stylecode="italics">(Hypericum perforatum)</content>
</td>
<td stylecode="Rrule">↓ sofosbuvir<br/>↓ GS-331007</td>
<td stylecode="Rrule">Coadministration of SOVALDI with St. John's wort, an intestinal P-gp inducer, is not recommended <content stylecode="italics">[see <linkhtml href="#S5.2">Warnings and Precautions (5.2)</linkhtml>].</content>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">HIV Protease Inhibitors:</content>
<br/>tipranavir/ritonavir</td>
<td stylecode="Rrule">↓ sofosbuvir<br/>↓ GS-331007</td>
<td stylecode="Rrule">Coadministration of SOVALDI with tipranavir/ritonavir is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of SOVALDI.  Coadministration is not recommended.</td>
</tr>
</tbody>
</table>